Specialty generics maker known for complex oncology drugs and aggressive patent-challenge (Para IV) launches in the US.
Specialty generics maker known for complex oncology drugs and aggressive patent-challenge (Para IV) launches in the US.
Relies on a small number of high-value US launches, typically in cancer treatment, so earnings jump when a launch is permitted and fall as competitors enter. The India business sells branded cancer drugs to hospitals. Founder V C Nannapaneni leads the company.
In one line: India's Para IV specialist, a smaller Teva.
Moat: narrow (IP / patents, process know-how). Expertise in complex generic litigation and first-to-file exclusivity wins are hard to replicate.
Headquarters: Hyderabad, India · Founded: 1981 · Employees: 5,060
Size NATCO Pharma (NATCOPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.73B, the 420th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹820.60 on 18 Nov 2026.
Performance Over six months the shares fell 27.4%, against +1.8% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 29.6% over the last twelve months (peer median +6.8%); the operating margin is 17.4% (peer median 7.8%).
Valuation It trades at 19.1× forward earnings against a peer median of 19.7× (9th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.7 points below its cost of capital (13.1% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹30.9B | ₹40.5B | ₹44.1B | ₹39.8B | ₹27.0B |
| Revenue growth | — | -8% | +11% | +47% | — |
| Gross profit | ₹15.8B | ₹21.7B | ₹26.4B | ₹22.9B | ₹12.0B |
| EBITDA | ₹7.31B | ₹14.9B | ₹22.5B | ₹18.2B | ₹9.69B |
| Net income | ₹8.29B | ₹14.2B | ₹18.9B | ₹13.9B | ₹7.15B |
| Free cash flow | n/a | ₹16.3B | ₹14.3B | ₹9.13B | ₹7.38B |
| Capital expenditure | n/a | ₹3.91B | ₹5.12B | ₹3.59B | ₹2.06B |
| Total debt | ₹10.3B | ₹7.14B | ₹2.79B | ₹3.71B | ₹1.76B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| NATCO Pharma NATCOPHARM.NS | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Biocon BIOCON.NS | $6.31B | -15% | +6% | 8% | 61.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NATCOPHARM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | -0.3% | 9th highest of 21 |
| 6-month return | -27.4% | +1.8% | 3rd lowest of 20 |
| Distance from 52-week high | -33.1% | -30.6% | 10th lowest of 21 |
| Revenue growth (TTM) | -29.6% | +6.8% | 2nd lowest of 20 |
| Operating margin | 17.4% | 7.8% | 5th highest of 20 |
| Forward P/E | 19.1× | 19.7× | 9th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 20.5% | 3.7% | 5th most demanding of 16 |
| Growth delivered (Del g) | +19.0% | +8.2% | 3rd highest of 16 |
| Hurdle (Req g minus delivered) | +1.5 pp | -6.2 pp | 7th most demanding of 16 |
| ROIC minus cost of capital | -8.7 pp | +1.2 pp | 6th lowest of 21 |
| EV / EBITDA | 21.4× | 18.1× | 4th most expensive of 8 |
| Net debt / EBITDA | -0.7× | -1.1× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |